Cargando…
Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
INTRODUCTION: Nusinersen was approved as the first treatment for all types of spinal muscular atrophy (SMA), including adults with SMA types 2 and 3. Robust biomarkers of treatment response in SMA adults are lacking. Our aim was to examine cerebrospinal fluid (CSF) amyloid‐β40 (Aβ40) and amyloid‐β42...
Autores principales: | Introna, Alessandro, Milella, Giammarco, D'Errico, Eustachio, Fraddosio, Angela, Scaglione, Gaspare, Ucci, Maria, Ruggieri, Maddalena, Simone, Isabella Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251706/ https://www.ncbi.nlm.nih.gov/pubmed/33660868 http://dx.doi.org/10.1002/mus.27212 |
Ejemplares similares
-
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience
por: Milella, Giammarco, et al.
Publicado: (2021) -
Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis
por: Milella, Giammarco, et al.
Publicado: (2022) -
Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021) -
Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype
por: Zoccolella, Stefano, et al.
Publicado: (2020) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)